Evidence map›Paper›PMID 26663361›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2016

Enhanced B Cell Alloantigen Presentation and Its Epigenetic Dysregulation in Liver Transplant Rejection.

M Ningappa, C Ashokkumar, B W Higgs, Q Sun, R Jaffe, G Mazariegos, D Li, D E Weeks, S Subramaniam, R Ferrell and 2 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03409341 (Personalizing Immune Checkpoint Inhibitor Therapy for Solid Tumors), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03409341 withdrawnnot on this mapstarted 2019, after this paper: background citation

Personalizing Immune Checkpoint Inhibitor Therapy for Solid Tumors

TypeobservationalSponsorHoly Cross Hospital, MarylandRan2019 to 2020Enrolled0ConditionsLung Cancer Stage IVArmsBlood and tumor tissue analysis, Clinical response.
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Operational tolerance in intestinal transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Genetics of acute rejection after kidney transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2018
    Review
  16. Translational medical research and liver transplantation: systematic review.Translational gastroenterology and hepatology · 2018
    Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

M NingappaHillman Center for Pediatric Transplantation, Thomas E. Starzl Transplantation Institute, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center Pittsburgh, PA.
C AshokkumarHillman Center for Pediatric Transplantation, Thomas E. Starzl Transplantation Institute, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center Pittsburgh, PA.
B W HiggsHillman Center for Pediatric Transplantation, Thomas E. Starzl Transplantation Institute, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center Pittsburgh, PA.
Q SunHillman Center for Pediatric Transplantation, Thomas E. Starzl Transplantation Institute, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center Pittsburgh, PA.
R JaffeDepartment of Pathology, University of Pittsburgh, Division of Pediatric Pathology, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center, Pittsburgh, PA.
G MazariegosHillman Center for Pediatric Transplantation, Thomas E. Starzl Transplantation Institute, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center Pittsburgh, PA.
D LiCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA.
D E WeeksDepartment of Human Genetics, University of Pittsburgh, Pittsburgh, PA.
S SubramaniamDepartment of Bioengineering, University of California, San Diego, La Jolla, CA.
R FerrellDepartment of Human Genetics, University of Pittsburgh, Pittsburgh, PA.
H HakonarsonCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA.
R SindhiHillman Center for Pediatric Transplantation, Thomas E. Starzl Transplantation Institute, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center Pittsburgh, PA.
Children's Hospital of Pittsburgh · USUniversity of Pittsburgh Medical Center · USChildren's Hospital of Philadelphia · USUniversity of Pittsburgh · USUniversity of California, San Diego · US

Funding

Predictors for drug selection and minimization in pediatric liver transplantationR01AI073895 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SINDHI, RAKESH K. · 2006 to 2009
$1.5M
NIAID NIH HHS 5R01AI073895-05NIAID NIH HHS R01 AI073895
6 · The paper itself

Abstract

T cell suppression prevents acute cellular rejection but causes life-threatening infections and malignancies. Previously, liver transplant (LTx) rejection in children was associated with the single-nucleotide polymorphism (SNP) rs9296068 upstream of the HLA-DOA gene. HLA-DOA inhibits B cell presentation of antigen, a potentially novel antirejection drug target. Using archived samples from 122 white pediatric LTx patients (including 77 described previously), we confirmed the association between rs9296068 and LTx rejection (p = 0.001, odds ratio [OR] 2.55). Next-generation sequencing revealed that the putative transcription factor (CCCTC binding factor [CTCF]) binding SNP locus rs2395304, in linkage disequilibrium with rs9296068 (D' 0.578, r(2) = 0.4), is also associated with LTx rejection (p = 0.008, OR 2.34). Furthermore, LTx rejection is associated with enhanced B cell presentation of donor antigen relative to HLA-nonidentical antigen in a novel cell-based assay and with a downregulated HLA-DOA gene in a subset of these children. In lymphoblastoid B (Raji) cells, rs2395304 coimmunoprecipitates with CTCF, and CTCF knockdown with morpholino antisense oligonucleotides enhances alloantigen presentation and downregulates the HLA-DOA gene, reproducing observations made with HLA-DOA knockdown and clinical rejection. Alloantigen presentation is suppressed by inhibitors of methylation and histone deacetylation, reproducing observations made during resolution of rejection. Enhanced donor antigen presentation by B cells and its epigenetic dysregulation via the HLA-DOA gene represent novel opportunities for surveillance and treatment of transplant rejection.

Indexed as

EpigenomicsAntigen PresentationBlotting, WesternB-LymphocytesCells, CulturedChildChromatin ImmunoprecipitationFemaleFollow-Up StudiesGenotypeGraft RejectionGraft SurvivalHLA AntigensHumansImmunoenzyme TechniquesIsoantigensHLA AntigensIsoantigensRNA, MessengerB cell biologyflow cytometrygenomicsimmuneimmunobiologyimmunosuppression/immune modulationliver transplantation/hepatologymonitoringrejection:acutetranslational research/science

Identifiers

PMID26663361
PMCPMC5082419
OpenAlexW2208619892

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.